Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CTSS | P25774 | 8/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30993196 | 1.00 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL28356427 | 0.88 | CTSK (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL7854592 | 0.84 | CTSK (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6326266 | 0.84 | CA1 (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL25166215 | 0.83 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL31059710 | 0.83 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL31059527 | 0.83 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL86185 | 0.82 | CTSK (0.56) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL86153 | 0.82 | CTSK (0.56) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL4118840 | 0.82 | CTSK (0.56) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025016906-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016909-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |